Li I Cheng

US Patent:

20200079877, Mar 12, 2020

Filed:

Nov 8, 2019

Appl. No.:

16/678165

Inventors:

- Cambridge, GB
Kris SACHSENMEIER - Gaithersburg MD, US
Erin SULT - Gaithersburg MD, US
Qihui Huang - Gaithersburg MD, US
Peter PAVLIK - Gaithersburg MD, US
Melissa DAMSCHRODER - Gaithersburg MD, US
Li CHENG - Gaithersburg MD, US
Gundo DIEDRICH - Gaithersburg MD, US
Jonathan RIOS-DORIA - Gaithersburg MD, US
Scott HAMMOND - Gaithersburg MD, US
Ralph MINTER - Cambridge, GB
Steve RUST - Cambridge, GB
Sandrine GUILLARD - Cambridge, GB
Robert HOLLINGSWORTH - Gaithersburg MD, US
Lutz JERMUTUS - Cambridge, GB
Nicholas DURHAM - Gaithersburg MD, US
Ching Ching LEOW - Gaithersburg MD, US
Mary ANTONYSAMY - Gaithersburg MD, US
James GEOGHEGAN - Gaithersburg MD, US
Xiaojun LU - Gaithersburg MD, US
Kim ROSENTHAL - Gaithersburg MD, US

International Classification:

C07K 16/40
A61K 47/68
C07K 16/28

Abstract:

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

US Patent:

20190292274, Sep 26, 2019

Filed:

Apr 4, 2019

Appl. No.:

16/375051

Inventors:

- Cambridge MA, US
Kris SACHSENMEIER - Gaithersburg MD, US
Erin SULT - Gaithersburg MD, US
Qihui HUANG - Gaithersburg MD, US
Peter PAVLIK - Gaithersburg MD, US
Melissa DAMSCHRODER - Gaithersburg MD, US
Li CHENG - Gaithersburg MD, US
Gundo DIEDRICH - Gaithersburg MD, US
Jonathan RIOS-DORIA - Gaithersburg MD, US
Scott HAMMOND - Gaithersburg MD, US
Ralph MINTER - Cambridge, GB
Steve RUST - Cambridge, GB
Sandrine GUILLARD - Cambridge, GB
Robert HOLLINGSWORTH - Gaithersburg MD, US
Lutz JERMUTUS - Cambridge, GB
Nicholas DURHAM - Gaithersburg MD, US
Ching Ching LEOW - Gaithersburg MD, US
Mary ANTONYSAMY - Gaithersburg MD, US
James GEOGHEGAN - Gaithersburg MD, US
Xiaojun LU - Gaithersburg MD, US
Kim ROSENTHAL - Gaithersburg MD, US

International Classification:

C07K 16/40
A61K 47/68
C07K 16/28

Abstract:

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

US Patent:

20180194858, Jul 12, 2018

Filed:

Feb 23, 2018

Appl. No.:

15/903649

Inventors:

- Cambridge, GB
Kris SACHSENMEIER - Gaithersburg MD, US
Erin SULT - Gaithersburg MD, US
Qihui Huang - Gaithersburg MD, US
Peter PAVLIK - Gaithersburg MD, US
Melissa DAMSCHRODER - Gaithersburg MD, US
Li CHENG - Gaithersburg MD, US
Gundo DIEDRICH - Gaithersburg MD, US
Jonathan RIOS-DORIA - Gaithersburg MD, US
Scott HAMMOND - Gaithersburg MD, US
Ralph MINTER - Cambridge, GB
Steve RUST - Cambridge, GB
Sandrine GUILLARD - Cambridge, GB
Robert HOLLINGSWORTH - Gaithersburg MD, US
Lutz JERMUTUS - Cambridge, GB
Nicholas DURHAM - Gaithersburg MD, US
Ching Ching LEOW - Gaithersburg MD, US
Mary ANTONYSAMY - Gaithersburg MD, US
James GEOGHEGAN - Gaithersburg MD, US
Xiaojun LU - Gaithersburg MD, US
Kim ROSENTHAL - Gaithersburg MD, US

International Classification:

C07K 16/40
A61K 47/68
C07K 16/28
A61K 39/00

Abstract:

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

US Patent:

20160194407, Jul 7, 2016

Filed:

Nov 9, 2015

Appl. No.:

14/936233

Inventors:

- Cambridge, GB
Kris Sachsenmeier - Gaithersburg MD, US
Erin Sult - Gaithersburg MD, US
Qihui Huang - Gaithersburg MD, US
Peter Pavlik - Gaithersburg MD, US
Melissa Damschroder - Gaithersburg MD, US
Li Cheng - Gaithersburg MD, US
Gundo Diedrich - Gaithersburg MD, US
Jonathan Rios-Doria - Gaithersburg MD, US
Scott Hammond - Gaithersburg MD, US
Ralph Minter - Cambridge, GB
Steve Rust - Cambridge, GB
Sandrine Guillard - Cambridge, GB
Robert Hollingsworth - Gaithersburg MD, US
Lutz Jermutus - Cambridge, GB
Nicholas Durham - Gaithersburg MD, US
Ching Ching Leow - Gaithersburg MD, US
Mary Antonysamy - Gaithersburg MD, US
James Geoghegan - Gaithersburg MD, US
Xiaojun Lu - Gaithersburg MD, US
Kim Rosenthal - Gaithersburg MD, US

International Classification:

C07K 16/40
C07K 16/28

Abstract:

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.